At the end of September 2019, Health Canada approved the BAQSIMI™ nasal glucagon, a new treatment for severe hypoglycemia. The highly anticipated drug is now available in Quebec pharmacies. With hypoglycemia being insulin’s main adverse effect, anyone living with type 1 diabetes is at risk. This risk affects their everyday life and their ability to … Read more Nasal Glucagon Now Available in Quebec!
A study that was presented at the September 2019 EASD Annual Meeting showed how difficult it is to achieve optimal blood sugar levels for those living with type 1 diabetes. As part of this study, data was collected in 17 countries in Western and Eastern Europe, Latin America, Asia and the Middle East (North America and … Read more Achieving Optimal Blood Sugar Control: A Real Challenge for People Living with Type 1 Diabetes
Since the year 2000, many studies have looked at the impact of closed-loop insulin delivery systems. We had mentioned this method of insulin administration, also called “artificial pancreas”, in a previous article. When using this technology, the basal insulin rate automatically adjusts according to the blood sugar level measured with a continuous blood glucose monitor … Read more Closed Loop Insulin Delivery: Impact on Blood Sugar in People Living with Type 1 Diabetes.
Factors that trigger the onset of type 1 diabetes for people who have a genetic predisposition are still not known with certainty. There are likely many environmental factors that contribute and lead to the destruction of insulin-producing pancreatic beta cells. New hypotheses Viral infections are among the likely suspects. We mentioned this hypothesis in a previous article, … Read more Viral Infections as a Potential Cause of Type 1 Diabetes for People with Genetic Predisposition
Continuous glucose monitoring (CGM) systems offer lots of benefits, including reducing—or even eliminating—finger pricks and making it easier to prevent hypoglycemia and hyperglycemia episodes. The technology has proven to be a revolution for many, but its high cost remains a significant drawback. Abbott’s own CGM system, the FreeStyle Libre, is covered under the … Read more Spotlight on RAMQ coverage for FreeStyle Libre
Each year, the European Association for the Study of Diabetes (EASD) presents the results of the latest diabetes research at its Annual Meeting. The last such event was held from September 16 to 20, 2019. Here are some of the hypoglycemia-related highlights: – Severe hypoglycemia (episodes that result in a loss of consciousness or need another … Read more Highlights and New Studies on Hypoglycemia in Type 1 Diabetes from the 2019 EASD Annual Meeting